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Setting the threshold for surgical prevention in women at increased risk of ovarian cancer 
Abstract 
The number of ovarian cancer cases is predicted to rise by 14% in Europe and 55% worldwide over 
the next two decades. The current absence of a screening programme, rising drug/treatment costs, 
and only marginal improvements in survival seen over the last 30 years, suggests the need for 
maximising primary surgical prevention to reduce the burden of ovarian cancer. Primary surgical 
prevention through risk-reducing salpingo-oophorectomy (RRSO) is well established as the most 
effective method for preventing ovarian cancer. In the UK it has traditionally been offered to high 
risk women (>10% lifetime risk of ovarian cancer) who have completed their family. The cost-
effectiveness of RRSO in BRCA1/BRCA2 carriers >35 years is well established.  Recently RRSO has 
been shown to be cost-effective in post-menopausal women at lifetime ovarian cancer risks ≥5% and 
in premenopausal women at lifetime risks >4%. The acceptability, uptake and satisfaction with RRSO 
at these intermediate-risk levels remain to be established. Prospective outcome data on risk-
reducing salpingectomy and delayed-oophorectomy for preventing ovarian cancer is lacking and 
hence, this is best offered for primary prevention within the context and safe environment of a 
clinical trial. An estimated 63% of ovarian cancers occur in women with >4% lifetime-risk and 53% in 
those with ≥5% lifetime-risk. RRSO can be offered for primary surgical prevention to women at 
intermediate risk levels (4-5% to 10%). This includes unaffected women who have completed their 
family and have RAD51C, RAD51D or BRIP1 gene mutations; first-degree relatives of women with 
invasive epithelial ovarian cancer; BRCA negative women from high-risk breast-&-ovarian cancer or 
ovarian cancer only families.  In those with BRCA1, RAD51C/RAD51D/MMR  mutations and the 
ocassional families with history of ovarian cancer in their 40s surgery needs to be considered at <45. 
In other moderate risk gene mutation carriers and those with polygenic risk, RRSO needs be 
considered at 50. There is need for establishment/expansion of well-defined pathways to increase 
clinical access to RRSO. It is time to lower the risk threshold for RRSO to enable introduction of a 
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targeted primary prevention approach which could significantly impact the future burden of ovarian 
cancer. 
 
Key Words: Ovarian Cancer, prevention, risk threshold, surgical prevention, salpingectomy, salpingo-
oophorectomy   
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The GLOBOCAN project of the International Agency for Research on Cancer (IARC) predicts that by 
2035 the number of cases of ovarian cancer will rise by 14% in Europe and 55% worldwide. It also 
estimates that the number of deaths from ovarian cancer will rise by 22% in Europe and by 67% 
worldwide over the same time.1 Advances in treatment strategies have resulted in only a small 
impact on survival over the last three decades.2 Both in the low risk UK Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS).3 and  the high risk women United Kingdom Familial Ovarian Cancer 
Screening Study (UKFOCSS) a CA125 based multimodal screening strategy has shown promise with 
significantly more women being diagnosed with earlier stage disease and lower tumour volume 
during screening.4 However in UKCTOCS there is as yet no conclusive mortality benefit. Hence unlike 
in breast or cervical cancer, screening programmes for ovarian cancer are not recommended. Even if 
a mortality benefit were proven on extended follow-up in UKCTOCS,5 primary prevention strategies 
remain the most proven method in reducing population burden of disease, with immunisation being 
a prime example. In ovarian cancer this translates into primary surgical prevention. Given the 
minimal impact observed with alternative strategies, and rising drug/treatment costs, maximising 
primary surgical prevention needs to be at the core of our efforts to reduce the burden of ovarian 
cancer in the future. This approach fits well with recent strategic initiatives which emphasise the 
need for greater focus on cancer prevention, such as the Independent Cancer Task Force, Cancer 
Strategy for England 2015-2020,6 and the Obama Precision Medicine initiative.7 
 
In the general population, the life time risk of ovarian cancer ranges from 1.3% to 2%.8, 9 In 
BRCA1/BRCA2 mutation carriers lifetime ovarian cancer risks range from 17%-44% and worldwide 
these women are considered to be at high risk.10-12 Historically, restricted access to BRCA testing in 
many countries (including the UK) led to women being classified on the basis of family history alone. 
In the UK we have historically defined women as being high risk if they are estimated to have a life 
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time risk of ovarian cancer of ≥10% .4, 13 This was the clinical threshold for screening and prevention 
used within the national UKFOCSS trial and followed in many high-risk clinics.4, 14, 15 This 
corresponded to the average estimate of ovarian cancer risk in untested women from high risk 
families. However, there was no well-defined scientific basis for this clinical convention. To the best 
of our knowledge, there are no ‘peer reviewed’ ‘published’ clinical guidelines anywhere which 
previously defined the ovarian cancer risk threshold for surgical prevention.   
 
In more recent years, high throughput next generation sequencing technologies and advances in 
computational bioinformatics have heralded significant change in this  genomic landscape. Firstly 
cheaper testing has led to many of the restrictions around BRCA testing to be removed. In the UK,  
for example since 2016, women who have never had cancer and are considered to be at a 10% risk 
of carrying the BRCA gene mutation are being offered testing. Secondly , a number of new moderate 
penetrance ovarian cancer gene mutations have been identified, such as RAD51C (lifetime ovarian 
cancer risk = 11.2%, CI: (5.7%, 21.3%)),16 RAD51D (lifetime ovarian cancer risk = 11.9%, CI: (5.7%, 
24.6%)17 and BRIP1 (lifetime ovarian cancer risk = 5.8%, CI: (3.65%, 9.1%).18 Confidence intervals of 
these estimates will narrow as more data accrue. Unlike BRCA1/BRCA2, mutations in these three 
moderate risk genes are not associated with an increased risk of breast cancer. Panel genetic testing 
for RAD51C, RAD51D and BRIP1 mutations (along with the traditional BRCA1/BRCA2 genes) is now 
available in clinical practice. Additionally a number of common genetic variants or Single Nucleotide 
Polymorphisms (SNPs) which impact ovarian cancer risk have been identified through genome wide 
association studies (GWAS).19, 20 While, the level of risk associated with each individual SNP is small 
(odds ratios range from 0.8 to 1.4), a combination of SNPs present together could have a 
multiplicative effect on risk in a single individual. The impact of the SNP profile is estimated through 
a polygenic risk score. This SNP profile/ polygenic risk score coupled with epidemiological variables 
(e.g. parity, age, endometriosis, tubal ligation, first degree relative with ovarian cancer, 
contraceptive pill use and BMI) have been incorporated into recently published risk models 
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developed by consortia like OCAC (Ovarian Cancer Action Consortium). These can predict ovarian 
cancer risk on a wider population basis.21, 22 Additionally, further model development work is being 
undertaken within OCAC and by others. A similar strategy is also being employed by large groups like 
CIMBA (Consortium of Investigators of Modifiers of BRCA1/2) to further improve the precision of risk 
estimates and enable stratification in high risk women such as BRCA1/BRCA2 carriers. BRCA1/BRCA2 
mutations are responsible for only 1/4th of the familial relative risk for ovarian cancer. A SNP based 
polygenic risk driven strategy has been shown to improve risk prediction in BRCA negative women 
with a strong family history of cancer.11 Ovarian cancer risk models incorporating epidemiologic 
factors, high penetrance genes, moderate penetrance genes and common genetic variants are also 
being developed and validated in the PROMISE (Predicting Risk of Ovarian Malignancy Improved 
Screening and Early detection) programme.23 Thus our ability to identify women at varying 
intermediate ranges of ovarian cancer risk has been significantly boosted. As more sophisticated 
models are developed and get validated over the coming years, clinical applicability will improve. 
 
In addition to lifetime risk, a critical factor is the age when risk begins to rise. For BRCA1 the risk 
begins to rise at 35 years (2% below age 40 rising to 5% if 2 or more first degree relatives with OC)12 
but becomes more significant after the age of 40 years. For BRCA2 this risk does not begin to rise 
before 40 years and becomes more significant after the age of 45 years. Hence, RRSO doesn’t need 
to be undertaken before 35-40 years in BRCA1 and can be delayed till 40-45 years in BRCA2 carriers. 
Ovarian cancers not linked to pathogenic mutations are more likely to present after the menopause, 
with risks beginning to rise after 50 years age. Decision making on whether to undergo RRSO ‘or not’ 
is a complex and dynamic process which changes with time.15 It can be affected by the age of the 
person, the history of cancer in self or family, presence of a gene mutation, the risks associated with 
premature menopause and personal preference. 
 
Risk reducing salpingo-oophorectomy (RRSO) 
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Primary surgical prevention through removal of both tubes and ovaries is well established as the 
most effective method for preventing ovarian cancer. It is routinely offered to high risk women who 
have completed their family with uptake rates of up to 70%,  satisfaction rates of up to 97% and 
regret rates of ~5%.15, 24 BRCA1/BRCA2 carriers undergoing this procedure benefit from a ~80% 
reduction in ovarian cancer risk,25 ~79% reduction in ovarian cancer specific mortality26 and ~60% 
reduction in all-cause mortality.26 A 2-4% post-surgical risk of primary peritoneal cancer (PPC) has 
been reported over 20 years. Average risk women undergoing bilateral salpingo-oophorectomy can 
also benefit from a ~94% reduction in ovarian cancer risk.27 This raises the issue of the ovarian 
cancer risk threshold at which primary surgical prevention should be offered more widely.  While 
cost-effectiveness of RRSO in BRCA1/BRCA2 carriers who are over 35 and have completed their 
families is well established,28 the cost-effectiveness at lower levels of risk was only recently reported. 
We developed decision analytic models to identify the ovarian cancer risk thresholds which would 
be appropriate for RRSO based primary surgical prevention in both pre-menopausal29 and post-
menopausal30 women. Decision modelling provides a logical, quantitative and transparent 
framework for evaluating costs and consequences (health outcomes) which result from a sequence 
of events following alternative treatment strategies. Cost-effectiveness analysis has been highlighted 
by the National Institute of Health and Care Excellence (NICE) as the favoured form of economic 
assessment to compare relative costs and health outcomes in decision modelling.31 The model 
outcome is described in terms of an incremental cost-effectiveness ratio (ICER) / quality adjusted 
life-year (QALY). This is compared with the standard NICE thresholds for cost-effectiveness of 
£20,000-30,000/QALY. We found RRSO undertaken at >50 years to be cost-effective in post-
menopausal women at a lifetime ovarian cancer risk of ≥5% (ICER = £15247/QALY). In 
premenopausal women undergoing RRSO at >40 years, the lifetime ovarian cancer risk threshold for 
RRSO was >4% (ICER = £19536/QALY). The modelling incorporates a detriment for excess deaths 
from coronary heart/cardiovascular disease reported in the literature.27 The gains in life expectancy 
were found to be >42.7 days in premenopausal and >29.2 days in post-menopausal women. These 
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levels are comparable to life expectancy gains of 11.6-32.4 days reported from other beneficial 
interventions such as cervical cancer screening.32 It is important to highlight that these life gains are 
averaged across the entire population and therefore, for an individual woman in whom an ovarian 
cancer is prevented, this figure is multiple times higher.  
 
In premenopausal women,  surgical menopause is associated with a detrimental impact on 
cardiovascular disease, sexual function, bone health, vasomotor symptoms and has potential 
neurological consequences. These side effects are predominantly seen in women who undergo RRSO 
under 45 years who are not on HRT.27 Hence two issues are critical – one is age at RRSO in 
premenopausal women and the second is compliance with HRT use post surgery.  It is only in those 
with BRCA1, RAD51C/RAD51D mutations and the ocassional families with history of ovarian cancer 
in their 40s that surgery needs to be considered below the age of 45. In other moderate risk gene 
mutation carriers and those with polygenic risk, RRSO needs be considered at 50. More detailed 
recommendations are listed in Table-1. Short-term HRT in women undergoing premature surgical 
menopause has not been shown to increase the risk of breast cancer.33 In premenopausal women 
who cannot take HRT, the lifetime ovarian cancer risk threshold for cost-effectiveness of RRSO at 
>40 years is higher at 8.2%.29  
 
Risk Reducing Salpingectomy (RRS) 
There is increasing acceptance of a central role for the tube in the etiopathogenesis of ovarian 
cancer. Serous tubal intraepithelial carcinoma (STIC) is established as a precursor lesion, present as a 
continuum with early tubal carcinomas, supporting transition from insitu to invasive cancer. This 
coupled with the detrimental consequences of premature surgical menopause from RRSO has led to 
the attractive proposition of premenopausal early salpingectomy and delayed oophorectomy (post-
menopausal) as a two-step approach for ovarian cancer prevention in high risk women. This has the 
advantage of providing reduction in ovarian cancer risk while avoiding the negative consequences of 
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early menopause. As a result some centres have changed protocols. However, prospective data 
showing the benefit of risk reducing salpingectomy in this two stage approach are lacking.  
Two large retrospective analyses in low-risk women suggests that salpingectomy offers a 35%-42% 
reduction in OC-risk. 34, 35 However, these data are retrospective, suffer from indication and 
detection bias and number of OCs are few. A recent systematic review reconfirms the limited and 
low-quality of available evidence on level of OC-risk reduction and ovarian function.36 Additionally 
data from the low-risk population cannot be directly extrapolated to higher risk women. We have 
recently shown that fimbrial tissue can persist on the ovarian surface despite salpingectomy in 16% 
women.37 The precise level of reduction in risk obtained from salpingectomy alone especially in 
women at increased risk is not known. Additionally salpingectomy will not prevent cancers that arise 
outside the tube. While 70% occult insitu/invasive cancers discovered at histology in women 
undergoing RRSO are tubal in origin, 30% are not.38 Our understanding of the biology of STICs and 
the interplay of the tube and the ovary in the development of ovarian cancer is incomplete. Initial 
data from a recent genomic analysis indicates that in cases where STICs co-exist with invasive high 
grade serous ovarian cancer (HGSOC), STICs may be precursors of HGSOC in only 50% cases.39 It has 
been suggested that a proportion of STICs may be metastatic to the tube and salpingectomy will not 
prevent ovarian cancer in these cases.40 The long term impact of RRS on ovarian function and onset 
of menopause is unknown. Although available short term data show no harmful impact on ovarian 
function, these studies have small sample sizes, use surrogate markers, and short duration of follow 
up. Short term hormonal function is not predictive of the final menstrual period or onset of 
menopause.41 Only longitudinal long term follow up data can address this question. A significant 
concern expressed by many is the attrition from delayed oophorectomy. It is possible some women 
may delay or not undergo post-menopausal oophorectomy and some may subsequently develop 
ovarian cancer. An additional gap in the literature is the lack of utility scores for salpingectomy. 
While one report in the literature suggests that a two-step approach could be cost-effective,42 the 
lack of prospective outcome data and various gaps in knowledge highlighted above preclude our 
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ability to draw conclusions and maintains significant uncertainty around this issue. The precise risk 
thresholds for offering this in routine practice remain to be determined. Hence, risk reducing 
salpingectomy (RRS) and delayed oophorectomy is best offered for primary prevention within the 
context and safe environment of a clinical trial. There are currently three trials on going – in The 
Netherlands (TUBA study NCT02321228),43 The USA (MD Anderson study NCT01907789) and France 
(Radical Fimbriectomy study NCT01608074).44 We found ~80% support amongst UK clinicians for 
such a study.45 A trial in the UK (PROTECTOR Study) is about to commence later this year. 
 
Changing the threshold for RRSO 
Data described above support offering RRSO for primary surgical prevention to women at 
intermediate levels of ovarian cancer risk, with lifetime risks ranging from 4-5% to 10%. Table-1 
summarises recommendations for RRSO based on clinical picture and level of risk. Changing the 
threshold for RRSO to these levels could have significant impact on disease burden as an estimated 
63% of ovarian cancers occur in women with >4% lifetime risk and 53% in those with a ≥5% lifetime 
risk.11 Modelling suggests that 13% of the female UK population have a >4% lifetime risk of ovarian 
cancer, while 9% has a ≥5% lifetime risk.11 Even without the new risk prediction models in clinical 
use, RRSO at these thresholds could immediately be offered to unaffected women who have 
completed their family and (a) have RAD51C, RAD51D or BRIP1 gene mutations; (b) are first degree 
relatives of women with invasive epithelial ovarian cancer;  or (c) are BRCA negative from high risk 
breast & ovarian cancer (HBOC) families or high risk ovarian cancer (HOC) families without a known 
pathogenic mutation in the family. While for RAD51C/RAD51D carriers this would be advised after 
the age of 40 years, in BRIP1 carriers as ovarian cancers have not yet been reported below the age of 
50 years. The timing of surgery could be delayed till 50 years in the bulk of the intermediate risk 





The acceptability, uptake and satisfaction with RRSO at these intermediate risk levels remain to be 
established. It is not known if the acceptability, uptake and satisfaction rates in intermediate risk 
women will be similar to the high levels found in high-risk women. The implementation of such an 
approach requires establishment or expansion of well-defined pathways to increase clinical access to 
RRSO. Additionally, it is critical for health professionals and women at risk to understand the 
importance of HRT following surgical menopause and to act on it to minimise/ ameliorate the 
potential detrimental long term health consequences. While HRT can ameliorate the negative side 
effects, it cannot completely alleviate all consequences (e.g. sexual dysfunction). These issues along 
with a ~3% reported surgical complication rate must form part of the informed decision making 
process. Patients need to be properly and thoroughly counselled on the benefits, disadvantages and 
complications of surgery for surgical prevention. Appropriately designed and developed information 
sheets/decision making materials can help facilitate this. Structures also need to be put in place to 
safeguard continued availability of HRT prescriptions as well as to monitor compliance and long term 
health. This could have health service resource and capacity implications. Looking ahead, the 
development and validation of more complex, state of the art risk models will provide the 
opportunity to stratify women in the general population by their absolute lifetime risk of ovarian 
cancer. The feasibility of such an approach is being tested in an ongoing pilot study.23 Wider 
implementation of a targeted surgical prevention strategy for women at >4-5% lifetime risk 
thresholds provides a huge opportunity for cost-effective targeted primary prevention. It is time for 
us to lower the risk threshold for RRSO to enable introduction of a primary prevention approach 
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Table-1: RRSO recommendations  
Clinical Category  Ovarian Cancer Risk  Recommended age (years) for RRSO*# Comments Reference 
BRCA1 mutation 
44% (range 40-60%)** 
Risks reported till <40 range from 0.6% - 
3.2% 
Risks between 40-50 years range from 6% - 
22% 









17% (range 12- 30%)** 
Risks reported till <40 range from 0-0.7% 
Risks between 40-50 years range from 0-4% 





RAD51C or RAD51D mutation 11-12% >40-50* 
Ovarian cancers have been reproted 
between ages 40-50 in RAD51C/RAD51D 
carriers (18% cancers in one series were 
between 40-50 years). Overall data are 
however limited and precise risk between 
40-50 is not well clarified. No cancers as 




BRIP1 mutation 5.80% >50* 
Overall data are limited and precise risk 
between 40-50 is not well clarified. 
Cancer has been reported in the 40-50 
age group (7% in a small series) but most 
occur at >50 years. 
Ramus 201518 
HBOC or HOC (untested) 
>7-10% (depends on FH/ pattern of 
distribution and ages of onset of cancers in 
the family) 







5-11% (depends on FH/ pattern of 
distribution and ages of onset of cancers in 
the family) 
>45*     
HBC only family BRCA-
Negative Population level Risk RRSO Not recommended 
Women from breast cancer only families 
who are BRCA negative on full screen 
analysis are not at increased risk of 
ovarian cancer. If the family history 
changes this risk estimation can change 
Ingham 2013 
1 FDR with ovarian cancer 
(BRCA unknown) ~5-6% >50* FRR ~3 (FRR ~3.6 for serous tumours) Jervis 2014
51 
2 ovarian cancer case families 
(BRCA unknown) ~7-10% >40-45* 
FRR ~4 (FRR~5.1 if exclude early BC 
families) Sutcliffe 2000
52 
≥3 ovarian cancer case 
families (BRCA unknown) ~12-14% >40-45* FRR ~7.45 Sutcliffe 2000
52 
1 FDR with ovarian cancer 
(BRCA Negative) ~3.5-4.5% (5.1% serous) 
RRSO could be considered 
after careful counselling 
paritcularly for serous 
histology (>50*) 
FRR ~2.25 (FRR is ~2.6 if OC is serous 
histology) Jervis 2014
51 
2 ovarian cancer case families 
(BRCA Negative) ~5-6% >50* FRR ~3 Sutcliffe 2000
52 
≥3 ovarian cancer case 
families (BRCA Negative) ~11% >40-45* FRR ~7 
Sutcliffe 2000, 
estimated52 
Polygenic (SNP) +/- 
Epidemiological based risk Model based estimation >4-5% risk >50*   
Jervis 2015, 
11Pearce 201521 
Lynch Syndrome: MLH1, 
MSH2, MSH6 mutations ~10% (6%-14%) 
>40* (combined with 
hysterectomy for EC risk) 
 Barrow 201353 
Lynch Syndrome: EPCAM 
deletion Not high risk for ovarian cancer RRSO Not recommended   
Ovarian cancer risk is not increased. EC 
risk 16% (Hysterectomy may be 




Lynch Syndrome: PMS2 
mutations 
Limited publsihed data to accurately 
quantify ovarian cancer risk 
RRSO not currently 
recommended 
(Hysterectomy may be 
considered for increased 
EC risk after 50) 
Evidence base for ovarian cancer risk is 
limited, though one paper suggests 
incresaed OC risk (SIR=12). RRSO is not 
currenlty recommended. This could 
change as more evidence accumulates. 







Additional risks to consider 
with Premenopausal 
oophorectomy 
Subfertility, premature menopause, increased sexual dysfunction; increased risk of osteoporosis; increasaed cardiovascular disease.  
Lack of HRT assocaited with increased cardiovascualr mortality; increased risk of neurological sequelae /cognitive dysfunction 
 
*Some families may have earlier onset ovarian cancers. RRSO may be undertaken up to 5 years before the earliest age of onset of ovarian cancer in the 
family.  
**higher end estimates are reported from estimates ascertained through high risk families attending cancer genetics clinics. Lower end estimates are from 
studies correcting for ascertainment. 
#Timing of RRSO needs to be decided after thorough counselling of pros and cons including surgical complications and after taking into account patients 
wishes, including fertility and premature menopause issues along with HRT use (premenopausal women)."     
FDR- First degree relative; FRR - familial relative risk; EC- endometrial cancer; HBC- high risk breast cancer only family; HBOC – high risk breast & ovarian 
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